Page data last changed: . Chemistry registry snapshot: . Registry refreshes and identity assessments are separate from scientific content review.
A seven-residue cyclic RGD peptide approved in China as an add-on antiplatelet agent for coronary stenting.
Also known as: Batifiban · BAT-2094 · Betagrin
Part of the Foundational & therapeutic peptides cluster
Overview
Bevifibatide (batifiban, Betagrin) is a synthetic cyclic heptapeptide (C34H47N11O9S2, ≈818 Da) built around the RGD integrin-binding motif. It antagonises the platelet αIIbβ3 (GP IIb/IIIa) and αvβ3 integrin receptors to inhibit aggregation. Developed by Bio-Thera Solutions, it was approved by China's NMPA on 25 June 2024 as an add-on to PCI, antiplatelet and anticoagulant therapy in acute coronary syndrome, and is in a phase 2 trial for acute ischaemic stroke.
Source & context
Biological / chemical source: Synthetic cyclic heptapeptide with an RGD motif closed by a disulfide
Primary research or clinical context: Approved in China (NMPA, 25 June 2024) for acute coronary syndrome patients undergoing percutaneous coronary intervention; investigational in acute ischaemic stroke
What bevifibatide is
Bevifibatide, also called batifiban and marketed in China as Betagrin, is a synthetic cyclic heptapeptide developed by Bio-Thera Solutions as an antiplatelet cardiovascular therapy. Its molecular formula is C34H47N11O9S2 and its mass about 818 Da. The IUPHAR/BPS Guide to Pharmacology describes it as an antagonist of the αIIbβ3 and αvβ3 integrin receptors designed to inhibit platelet aggregation. The one-letter sequence CRGDWPC contains the Arg-Gly-Asp (RGD) motif that integrins recognise, held in a ring by a disulfide between an N-terminal mercaptopropionyl group and the C-terminal cysteine, with a C-terminal amide (PubChem record).
Mechanism: blocking the final common pathway of platelet aggregation
Platelet aggregation ends with fibrinogen bridging activated αIIbβ3 (glycoprotein IIb/IIIa) receptors on adjacent platelets. An RGD-containing cyclic peptide occupies the fibrinogen-binding site and prevents that bridge. Bevifibatide also antagonises αvβ3, an integrin involved in vascular cell adhesion (IUPHAR record). This is the same class of mechanism as eptifibatide, the cyclic heptapeptide GP IIb/IIIa inhibitor already on this site; both are small, disulfide-cyclised RGD-type peptides used around percutaneous coronary intervention.
Clinical evidence: BES-PCI
BES-PCI was a multicentre, randomised, double-blinded, placebo-controlled phase III trial of bevifibatide in patients with acute coronary syndrome undergoing percutaneous coronary intervention, run across Chinese cardiology centres including Zhongshan Hospital (Fudan University), Tongji Hospital, Tianjin People's Hospital and others (Wu et al., Chinese Medical Journal 2025). The evidence pack contains the trial's registration and author list but not its numerical results, so no efficacy figures are quoted here; the approval described below rests on this programme.
Regulatory status as of September 2026
On 25 June 2024, bevifibatide received approval in China for patients with a clear diagnosis of acute coronary syndrome who need PCI, including coronary stenting, to reduce the risk of acute occlusion, stent thrombosis, no-reflow and slow blood flow; the first approval is as an add-on to PCI, antiplatelet and anticoagulant treatment (Fung, Drugs 2026). It is not approved in the United States, Canada or the European Union. ClinicalTrials.gov lists one recruiting phase 2 dose-response trial in acute ischaemic stroke (NCT06712004), consistent with the IUPHAR note that it is under investigation for anticoagulant efficacy in stroke.
How it relates to other peptides on this site
Eptifibatide is the closest relative: a cyclic heptapeptide GP IIb/IIIa antagonist derived from a snake-venom disintegrin and approved in Western markets for decades. Bivalirudin, also on this site, is a peptide anticoagulant that inhibits thrombin rather than platelets, and is used in the same PCI setting. Bevifibatide is a prescription hospital medicine; this profile is educational and not clinical guidance.
Sequence
One-letter sequence commonly cited for Bevifibatide (educational; isoforms and modifications may differ):
CRGDWPC
Residues plotted ~100° apart around an α-helix — clustering of one color reveals an amphipathic face.
Structure & chemistry
Molecular identity & reference confidence
Source-supported reference
Reference values are taken from the cited molecular record or curated profile. A database match is not independent laboratory verification; modifications, counter-ions, and formulations can change the measured mass.
- Molecular form
- Cyclic heptapeptide (CRGDWPC) containing the Arg-Gly-Asp integrin-recognition motif
- Species
- Not established by this molecular identity audit
- Termini (N / C)
- Not specified / Amide
Average reference mass
Reference policy updated: 2026-10-05
- IUPHAR/BPS source snapshot · 2026-10-01
- PubChem molecular record · 2026-10-01
N2-(3-mercaptopropionyl)-R-G-D-W-P-C-NH2, cyclised by a disulfide between the mercaptopropionyl group and Cys7
- Molecular formula
- C34H47N11O9S2
- Average reference mass
- ≈ 817.9
- Receptors
- αIIbβ3 integrin (GP IIb/IIIa) and αvβ3 integrin — antagonist
- Backbone
- Cyclic heptapeptide (CRGDWPC) containing the Arg-Gly-Asp integrin-recognition motif
- C-terminus
- Amide
- Status
- Approved in China (NMPA, June 2024) for ACS with PCI; not approved in the US, Canada or EU as of September 2026
- PubChem CID: 71556891
- IUPHAR ligand: 13953
- CAS RN: 710312-77-9
- UNII: 7AKM76YKN5
Chemistry values: curated profile, PubChem, IUPHAR/BPS Guide to Pharmacology · fetched 2026-10-01.
Clinical development snapshot
ClinicalTrials.gov lists 1 registered study with “Bevifibatide” as an intervention (snapshot 2026-09-07). A registry footprint is not evidence of efficacy or approval.
| NCT | Title | Phase | Status | Updated |
|---|---|---|---|---|
| NCT06712004 | A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke | Phase 2 | recruiting | 2025-07-17 |
Bevifibatide — reconstitution calculator
Enter how much peptide is in the vial and how much diluent (e.g. bacteriostatic water) is added. The tool returns the resulting solution concentration — and, for any amount you type, the volume it corresponds to. This is educational arithmetic, not a dosing recommendation.
Reference form: Cyclic heptapeptide (CRGDWPC) containing the Arg-Gly-Asp integrin-recognition motifAverage reference mass: 817.9 Da
Enter an amount to see the volume it corresponds to.
Educational concentration mathematics only. This tool does not recommend a dose, amount, or protocol, and nothing here is medical advice. Many peptides are not authorized by Health Canada for human use — see our reconstitution and bacteriostatic-water guides for context.
Change log
Dated observations from the data pipeline (registry flags, trial footprints, identifiers) and editorial reviews of this profile.
- IdentifiersCross-linked to IUPHAR ligand 13953 and PubChem CID 71556891.
- TrialsClinicalTrials.gov snapshot added: 1 registered study, highest phase 2.
- EditorialProfile content reviewed and updated by the editorial team.
FAQ about Bevifibatide
What is Bevifibatide?+
Bevifibatide (batifiban, Betagrin) is a synthetic cyclic heptapeptide (C34H47N11O9S2, ≈818 Da) built around the RGD integrin-binding motif. It antagonises the platelet αIIbβ3 (GP IIb/IIIa) and αvβ3 integrin receptors to inhibit aggregation. Developed by Bio-Thera Solutions, it was approved by China's NMPA on 25 June 2024 as an add-on to PCI, antiplatelet and anticoagulant therapy in acute coronary syndrome, and is in a phase 2 trial for acute ischaemic stroke.
What Canadian product status is recorded for Bevifibatide?+
Canadian product status for Bevifibatide has not been verified in this profile. No verified record here does not mean no authorization exists. Status depends on the product, formulation and use; consult Health Canada's product records.
What is the typical length of Bevifibatide?+
Bevifibatide is commonly described as approximately 7 amino acids (Cyclic RGD heptapeptide (integrin antagonist)).
What is bevifibatide?+
A synthetic cyclic RGD heptapeptide (batifiban, Betagrin) that blocks the platelet αIIbβ3 and αvβ3 integrins to inhibit aggregation, developed by Bio-Thera Solutions.
Is bevifibatide approved?+
In China, yes — NMPA approval on 25 June 2024 for acute coronary syndrome patients undergoing PCI. Not approved in the US, Canada or EU as of September 2026.
How does bevifibatide compare with eptifibatide?+
Both are cyclic heptapeptide GP IIb/IIIa antagonists used around coronary intervention; eptifibatide is approved in Western markets, bevifibatide in China.
Is bevifibatide being studied for stroke?+
Yes — a phase 2 dose-response trial in acute ischaemic stroke was recruiting as of September 2026.
Related peptides
References & further reading
- 1.Fung S (2026). Bevifibatide: First Approval. Drugs
- 2.Wu H et al. (2025). Efficacy and safety of bevifibatide in patients with acute coronary syndrome undergoing percutaneous coronary intervention (BES-PCI): a multicenter, randomized, double-blinded, placebo-controlled, phase III trial. Chin Med J (Engl)
- 3.PubChem — compound summary for Bevifibatide (CID 71556891)
- 4.ClinicalTrials.gov NCT06712004 — A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke